<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Musculoskelet Disord</journal-id><journal-title>BMC Musculoskeletal Disorders</journal-title><issn pub-type="epub">1471-2474</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">11860612</article-id><article-id pub-id-type="pmc">65524</article-id><article-id pub-id-type="publisher-id">1471-2474-3-2</article-id><article-id pub-id-type="doi">10.1186/1471-2474-3-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Norepinephrine-evoked pain in fibromyalgia. A randomized pilot study [ISRCTN70707830]</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Martinez-Lavin</surname><given-names>Manuel</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>mmlavin@infosel.net.mx</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Vidal</surname><given-names>Marcela</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>Dr4u505@aol.com</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Barbosa</surname><given-names>Rosa-Elda</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>rebcob@yahoo.com</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Pineda</surname><given-names>Carlos</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>carpineda@yahoo.com</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Casanova</surname><given-names>Jose-Miguel</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>casanova6951@terra.com.mx</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Nava</surname><given-names>Arnulfo</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>navazava@hotmail.com</email></contrib></contrib-group><aff id="I1"><label>1</label>Rheumatology Department Instituto Nacional de Cardiología Ignacio Chávez. Juan Badiano 1, 14080 Mexico D.F. México</aff><pub-date pub-type="collection"><year>2002</year></pub-date><pub-date pub-type="epub"><day>16</day><month>1</month><year>2002</year></pub-date><volume>3</volume><fpage>2</fpage><lpage>2</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2474/3/2"></ext-link><history><date date-type="received"><day>8</day><month>10</month><year>2001</year></date><date date-type="accepted"><day>16</day><month>1</month><year>2002</year></date></history><permissions><copyright-statement>Copyright © 2002 Martinez-Lavin et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.</copyright-statement><copyright-year>2002</copyright-year><copyright-holder>Martinez-Lavin et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.</copyright-holder></permissions><abstract><sec><title><offsets xml_i="3433" xml_f="3443" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="3454" xml_f="3943" txt_i="22" txt_f="511">Fibromyalgia syndrome displays sympathetically maintained pain features such as frequent post-traumatic onset and stimuli-independent pain accompanied by allodynia and paresthesias. Heart rate variability studies showed that fibromyalgia patients have changes consistent with ongoing sympathetic hyperactivity. Norepinephrine-evoked pain test is used to assess sympathetically maintained pain syndromes. Our objective was to define if fibromyalgia patients have norepinephrine-evoked pain.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="3984" xml_f="3991" txt_i="513" txt_f="520">Methods</offsets></title><p><offsets xml_i="4002" xml_f="4725" txt_i="521" txt_f="1244">Prospective double blind controlled study. Participants: Twenty FM patients, and two age/sex matched control groups; 20 rheumatoid arthritis patients and 20 healthy controls. Ten micrograms of norepinephrine diluted in 0.1 ml of saline solution were injected in a forearm. The contrasting substance, 0.1 ml of saline solution alone, was injected in the opposite forearm. Maximum local pain elicited during the 5 minutes post-injection was graded on a visual analog scale (VAS). Norepinephrine-evoked pain was diagnosed when norepinephrine injection induced greater pain than placebo injection. Intensity of norepinephrine-evoked pain was calculated as the difference between norepinephrine minus placebo-induced VAS scores.</offsets></p></sec><sec><title><offsets xml_i="4747" xml_f="4754" txt_i="1246" txt_f="1253">Results</offsets></title><p><offsets xml_i="4765" xml_f="5188" txt_i="1254" txt_f="1671">Norepinephrine-evoked pain was seen in 80 % of FM patients (95% confidence intervals 56.3 – 94.3%), in 30 % of rheumatoid arthritis patients and in 30 % of healthy controls (95% confidence intervals 11.9 – 54.3) (p &lt; 0.05). Intensity of norepinephrine-evoked pain was greater in FM patients (mean ± SD 2.5 ± 2.5) when compared to rheumatoid arthritis patients (0.3 ± 0.7), and healthy controls (0.3 ± 0.8) p &lt; 0.0001.</offsets></p></sec><sec><title><offsets xml_i="5210" xml_f="5221" txt_i="1673" txt_f="1684">Conclusions</offsets></title><p><offsets xml_i="5232" xml_f="5392" txt_i="1685" txt_f="1845">Fibromyalgia patients have norepinephrine-evoked pain. This finding supports the hypothesis that fibromyalgia may be a sympathetically maintained pain syndrome.</offsets></p></sec></abstract></article-meta></front><body><sec><title><offsets xml_i="5454" xml_f="5464" txt_i="1854" txt_f="1864">Background</offsets></title><p><offsets xml_i="5475" xml_f="5709" txt_i="1865" txt_f="2099">Several groups of investigators, using heart rate variability analysis have shown that fibromyalgia (FM) patients have changes consistent with persistent sympathetic hyperactivity and concurrent hypo-reactivity to orthostatic stress [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="5740" xml_f="5741" txt_i="2099" txt_f="2100">1</offsets></xref><offsets xml_i="5748" xml_f="5749" txt_i="2100" txt_f="2101">-</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="5780" xml_f="5781" txt_i="2101" txt_f="2102">6</offsets></xref><offsets xml_i="5788" xml_f="5892" txt_i="2102" txt_f="2206">]. This body of evidence led to the proposal that FM may be a sympathetically maintained pain syndrome [</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="5923" xml_f="5924" txt_i="2206" txt_f="2207">7</offsets></xref><offsets xml_i="5931" xml_f="6131" txt_i="2207" txt_f="2407">]. This pathogenesis would explain the peculiar pain syndrome that FM patients display, as well as the remaining manifestations that this illness exhibits in different organs and systems of the body [</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="6162" xml_f="6163" txt_i="2407" txt_f="2408">8</offsets></xref><offsets xml_i="6170" xml_f="6172" txt_i="2408" txt_f="2410">].</offsets></p><p><offsets xml_i="6179" xml_f="6617" txt_i="2411" txt_f="2849">Norepinephrine (NE)-evoked pain is the most widely used clinical research test to define sympathetically maintained pain syndromes. Several studies have shown that different types of neuropathic pain previously submissive to sympatholytic therapy are rekindled by cutaneous application of NE. Ali et al described 12 patients with reflex sympathetic dystrophy (complex regional pain syndrome type I) in whom NE application rekindled pain [</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="6648" xml_f="6649" txt_i="2849" txt_f="2850">9</offsets></xref><offsets xml_i="6656" xml_f="6792" txt_i="2850" txt_f="2986">]. Torebjork et al. described that NE application can aggravate the pain in some, but not all sympathetically maintained pain patients [</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="6824" xml_f="6826" txt_i="2986" txt_f="2988">10</offsets></xref><offsets xml_i="6833" xml_f="6995" txt_i="2988" txt_f="3150">]. Davis et al reported that the alpha 2-adrenergic agonist clonidine, delivered by transdermal patches relieves hyperalgesia in sympathetically maintained pain [</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="7027" xml_f="7029" txt_i="3150" txt_f="3152">11</offsets></xref><offsets xml_i="7036" xml_f="7226" txt_i="3152" txt_f="3342">]. Clonidine activates pre-synaptic adrenergic autoreceptors resulting in a reduction of norepinephrine release. This effectively decreases activation of the post-synaptic alpha 1 receptors.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="7267" xml_f="7274" txt_i="3344" txt_f="3351">Methods</offsets></title><sec><title><offsets xml_i="7294" xml_f="7306" txt_i="3352" txt_f="3364">Participants</offsets></title><p><offsets xml_i="7317" xml_f="7645" txt_i="3365" txt_f="3693">We studied 20 patients with FM and two age (+/- 5 years) and sex matched control groups, namely: 20 patients with rheumatoid arthritis (RA) and 20 apparently healthy persons. The eligibility criteria for the 3 different groups were as follows: for FM patients, to fulfill the 1990 ACR classification criteria for this syndrome [</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="7677" xml_f="7679" txt_i="3693" txt_f="3695">12</offsets></xref><offsets xml_i="7686" xml_f="7778" txt_i="3695" txt_f="3787">] and absence of comorbidity. For RA; to fulfill the corresponding classification criteria [</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="7810" xml_f="7812" txt_i="3787" txt_f="3789">13</offsets></xref><offsets xml_i="7819" xml_f="7969" txt_i="3789" txt_f="3939">] and to have an active disease. An exclusion clause for both control groups was the presence of widespread pain and/or more than 11 FM tender points.</offsets></p><p><offsets xml_i="7976" xml_f="8189" txt_i="3940" txt_f="4153">Analgesic/anti-inflammatory medications were not allowed in the immediate 24 hr. before the study. All subjects signed an informed consent form. The Human Research Committee of our Institute approved the protocol.</offsets></p></sec><sec><title><offsets xml_i="8211" xml_f="8224" txt_i="4155" txt_f="4168">Interventions</offsets></title><p><offsets xml_i="8235" xml_f="8500" txt_i="4169" txt_f="4434">The day of the study, subjects filled out a 10 cm visual analog scale for pain, fatigue, sleep difficulties, morning stiffness and disability, as well as a structured questionnaire about the presence of the distinctive features of FM according to the ACR criteria [</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="8532" xml_f="8534" txt_i="4434" txt_f="4436">12</offsets></xref><offsets xml_i="8541" xml_f="8629" txt_i="4436" txt_f="4524">] and of chronic fatigue syndrome according to the International Study Group criteria. [</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="8661" xml_f="8663" txt_i="4524" txt_f="4526">14</offsets></xref><offsets xml_i="8670" xml_f="9019" txt_i="4526" txt_f="4875">]. Norepinephrine (NE) was administered under a double blind protocol. Using insulin syringes with 29 gauge needles, 10 micrograms of NE diluted in 0.1 ml of normal saline solution or 0.1 ml of normal saline solution alone were injected subcutaneously in the volar aspect of a forearm. The contrasting substance was injected in the opposite forearm.</offsets></p></sec><sec><title><offsets xml_i="9041" xml_f="9050" txt_i="4877" txt_f="4886">Objective</offsets></title><p><offsets xml_i="9061" xml_f="9132" txt_i="4887" txt_f="4958">To define if subcutaneous injections of NE induces pain in FM patients.</offsets></p></sec><sec><title><offsets xml_i="9154" xml_f="9170" txt_i="4960" txt_f="4976">Outcome measures</offsets></title><p><offsets xml_i="9181" xml_f="9554" txt_i="4977" txt_f="5350">Subjects graded on a 10 cm visual analog scale (VAS), the maximum local pain elicited during the 5 minutes post-injection. NE-evoked pain was diagnosed when NE injection induced greater pain than placebo injection. Intensity of NE-evoked pain was calculated as the difference between the VAS score in the NE-injected forearm minus VAS score in the placebo-injected forearm.</offsets></p><p><offsets xml_i="9561" xml_f="9601" txt_i="5351" txt_f="5391">Associated adverse events were recorded.</offsets></p></sec><sec><title><offsets xml_i="9623" xml_f="9634" txt_i="5393" txt_f="5404">Sample size</offsets></title><p><offsets xml_i="9645" xml_f="9816" txt_i="5405" txt_f="5576">It was arbitrarily set at 20 participants per group. This is a pilot study, we had no pre-trial information on the expected response to NE for RA patients and FM patients.</offsets></p></sec><sec><title><offsets xml_i="9838" xml_f="9872" txt_i="5578" txt_f="5612">Randomization, sequence generation</offsets></title><p><offsets xml_i="9883" xml_f="10009" txt_i="5613" txt_f="5739">A coin flip was used to allocate the intervention sequence placebo-NE for each participant. Left forearms were injected first.</offsets></p></sec><sec><title><offsets xml_i="10031" xml_f="10066" txt_i="5741" txt_f="5776">Allocation concealment and blinding</offsets></title><p><offsets xml_i="10077" xml_f="10299" txt_i="5777" txt_f="5999">The physician who performed the injections was blinded as to the substance she was administering, she was not blinded as to patient's diagnosis. Injected substance identity was concealed until after outcomes were measured.</offsets></p></sec><sec><title><offsets xml_i="10321" xml_f="10340" txt_i="6001" txt_f="6020">Statistical methods</offsets></title><p><offsets xml_i="10351" xml_f="10701" txt_i="6021" txt_f="6371">Mean and standard deviation are used for descriptive values. Binomial distributed values are calculated as proportion with its 95% confidence intervals. Chi square analysis is used to compare qualitative variables. One-way analysis of variance to compare continuous variables. Bonferroni's multiple comparison test to define inter-group differences. </offsets><italic><offsets xml_i="10709" xml_f="10710" txt_i="6371" txt_f="6372">P</offsets></italic><offsets xml_i="10719" xml_f="10765" txt_i="6372" txt_f="6415"> values &lt; 0.05 were considered significant.</offsets></p></sec></sec><sec><title><offsets xml_i="10793" xml_f="10800" txt_i="6418" txt_f="6425">Results</offsets></title><sec><title><offsets xml_i="10820" xml_f="10833" txt_i="6426" txt_f="6439">Baseline data</offsets></title><p><offsets xml_i="10844" xml_f="10868" txt_i="6440" txt_f="6464">It is outlined in table </offsets><xref ref-type="table" rid="T1"><offsets xml_i="10900" xml_f="10901" txt_i="6464" txt_f="6465">1</offsets></xref><offsets xml_i="10908" xml_f="10981" txt_i="6465" txt_f="6538">. Ninety percent of FM patients were female. Their mean age was 43 years.</offsets></p><table-wrap position="float" id="T1"><label><offsets xml_i="11029" xml_f="11036" txt_i="6539" txt_f="6546">Table 1</offsets></label><caption><p><offsets xml_i="11056" xml_f="11133" txt_i="6546" txt_f="6623">Baseline Data of Fibromyalgia Patients and Two Age/Sex Matched Control Groups</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center"><bold><offsets xml_i="11229" xml_f="11241" txt_i="6625" txt_f="6637">Fibromyalgia</offsets></bold></td><td align="center"><bold><offsets xml_i="11278" xml_f="11298" txt_i="6638" txt_f="6658">Rheumatoid arthritis</offsets></bold></td><td align="center"><bold><offsets xml_i="11335" xml_f="11351" txt_i="6659" txt_f="6675">Healthy controls</offsets></bold></td></tr><tr><td></td><td align="center"><bold><offsets xml_i="11406" xml_f="11414" txt_i="6677" txt_f="6685">(n = 20)</offsets></bold></td><td align="center"><bold><offsets xml_i="11451" xml_f="11459" txt_i="6686" txt_f="6694">(n = 20)</offsets></bold></td><td align="center"><bold><offsets xml_i="11496" xml_f="11504" txt_i="6695" txt_f="6703">(n = 20)</offsets></bold></td></tr></thead><tbody><tr><td align="left"><offsets xml_i="11557" xml_f="11572" txt_i="6704" txt_f="6719">Age (mean ± SD)</offsets></td><td align="center"><offsets xml_i="11596" xml_f="11607" txt_i="6720" txt_f="6731">43.0 ± 15.2</offsets></td><td align="center"><offsets xml_i="11631" xml_f="11642" txt_i="6732" txt_f="6743">45.4 ± 13.1</offsets></td><td align="center"><offsets xml_i="11666" xml_f="11677" txt_i="6744" txt_f="6755">42.1 ± 14.8</offsets></td></tr><tr><td align="left"><offsets xml_i="11708" xml_f="11720" txt_i="6756" txt_f="6768">Gender (F/M)</offsets></td><td align="center"><offsets xml_i="11744" xml_f="11750" txt_i="6769" txt_f="6775">(18/2)</offsets></td><td align="center"><offsets xml_i="11774" xml_f="11780" txt_i="6776" txt_f="6782">(18/2)</offsets></td><td align="center"><offsets xml_i="11804" xml_f="11810" txt_i="6783" txt_f="6789">(18/2)</offsets></td></tr><tr><td align="left"><offsets xml_i="11841" xml_f="11879" txt_i="6790" txt_f="6828">Total fibromyalgia points, (mean ± SD)</offsets></td><td align="center"><offsets xml_i="11903" xml_f="11913" txt_i="6829" txt_f="6839">16.8 ± 1.9</offsets><sup><offsets xml_i="11918" xml_f="11919" txt_i="6839" txt_f="6840">*</offsets></sup></td><td align="center"><offsets xml_i="11949" xml_f="11958" txt_i="6841" txt_f="6850">1.3 ± 1.7</offsets></td><td align="center"><offsets xml_i="11982" xml_f="11991" txt_i="6851" txt_f="6860">0.7 ± 1.5</offsets></td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left"><bold><offsets xml_i="12067" xml_f="12089" txt_i="6862" txt_f="6884">VAS score, (mean ± SD)</offsets></bold></td><td></td><td></td><td></td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left"><offsets xml_i="12193" xml_f="12197" txt_i="6889" txt_f="6893">Pain</offsets></td><td align="center"><offsets xml_i="12221" xml_f="12230" txt_i="6894" txt_f="6903">6.5 ± 2.5</offsets><sup><offsets xml_i="12235" xml_f="12237" txt_i="6903" txt_f="6905">**</offsets></sup></td><td align="center"><offsets xml_i="12267" xml_f="12276" txt_i="6906" txt_f="6915">4.3 ± 2.5</offsets></td><td align="center"><offsets xml_i="12300" xml_f="12305" txt_i="6916" txt_f="6921">0 ± 0</offsets></td></tr><tr><td align="left"><offsets xml_i="12336" xml_f="12343" txt_i="6922" txt_f="6929">Fatigue</offsets></td><td align="center"><offsets xml_i="12367" xml_f="12376" txt_i="6930" txt_f="6939">7.2 ± 2.4</offsets><sup><offsets xml_i="12381" xml_f="12382" txt_i="6939" txt_f="6940">*</offsets></sup></td><td align="center"><offsets xml_i="12412" xml_f="12421" txt_i="6941" txt_f="6950">2.6 ± 2.5</offsets></td><td align="center"><offsets xml_i="12445" xml_f="12454" txt_i="6951" txt_f="6960">0.5 ± 1.3</offsets></td></tr><tr><td align="left"><offsets xml_i="12485" xml_f="12503" txt_i="6961" txt_f="6979">Sleep disturbances</offsets></td><td align="center"><offsets xml_i="12527" xml_f="12536" txt_i="6980" txt_f="6989">5.9 ± 2.6</offsets><sup><offsets xml_i="12541" xml_f="12542" txt_i="6989" txt_f="6990">*</offsets></sup></td><td align="center"><offsets xml_i="12572" xml_f="12581" txt_i="6991" txt_f="7000">2.0 ± 2.5</offsets></td><td align="center"><offsets xml_i="12605" xml_f="12614" txt_i="7001" txt_f="7010">0.2 ± 1.1</offsets></td></tr><tr><td align="left"><offsets xml_i="12645" xml_f="12662" txt_i="7011" txt_f="7028">Morning stiffness</offsets></td><td align="center"><offsets xml_i="12686" xml_f="12695" txt_i="7029" txt_f="7038">4.8 ± 3.7</offsets><sup><offsets xml_i="12700" xml_f="12702" txt_i="7038" txt_f="7040">**</offsets></sup></td><td align="center"><offsets xml_i="12732" xml_f="12741" txt_i="7041" txt_f="7050">2.4 ± 2.6</offsets></td><td align="center"><offsets xml_i="12765" xml_f="12774" txt_i="7051" txt_f="7060">0.2 ± 0.7</offsets></td></tr><tr><td align="left"><offsets xml_i="12805" xml_f="12815" txt_i="7061" txt_f="7071">Disability</offsets></td><td align="center"><offsets xml_i="12839" xml_f="12848" txt_i="7072" txt_f="7081">7.1 ± 2.2</offsets><sup><offsets xml_i="12853" xml_f="12854" txt_i="7081" txt_f="7082">*</offsets></sup></td><td align="center"><offsets xml_i="12884" xml_f="12893" txt_i="7083" txt_f="7092">3.1 ± 3.2</offsets></td><td align="center"><offsets xml_i="12917" xml_f="12926" txt_i="7093" txt_f="7102">0.2 ± 0.6</offsets></td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left"><bold><offsets xml_i="13002" xml_f="13051" txt_i="7104" txt_f="7153">Symptoms, % of patients (95% confidence interval)</offsets></bold></td><td></td><td></td><td></td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left"><offsets xml_i="13155" xml_f="13162" txt_i="7158" txt_f="7165">Anxiety</offsets></td><td align="center"><offsets xml_i="13186" xml_f="13200" txt_i="7166" txt_f="7180">90 (68.3–98.8)</offsets><sup><offsets xml_i="13205" xml_f="13206" txt_i="7180" txt_f="7181">*</offsets></sup></td><td align="center"><offsets xml_i="13236" xml_f="13250" txt_i="7182" txt_f="7196">45 (23.0–68.5)</offsets></td><td align="center"><offsets xml_i="13274" xml_f="13287" txt_i="7197" txt_f="7210">40(19.1–63.9)</offsets></td></tr><tr><td align="left"><offsets xml_i="13318" xml_f="13326" txt_i="7211" txt_f="7219">Headache</offsets></td><td align="center"><offsets xml_i="13350" xml_f="13364" txt_i="7220" txt_f="7234">90 (68.3–98.8)</offsets><sup><offsets xml_i="13369" xml_f="13370" txt_i="7234" txt_f="7235">*</offsets></sup></td><td align="center"><offsets xml_i="13400" xml_f="13413" txt_i="7236" txt_f="7249">35(15.4–59.2)</offsets></td><td align="center"><offsets xml_i="13437" xml_f="13449" txt_i="7250" txt_f="7262">25(8.7–49.1)</offsets></td></tr><tr><td align="left"><offsets xml_i="13480" xml_f="13488" txt_i="7263" txt_f="7271">Weakness</offsets></td><td align="center"><offsets xml_i="13512" xml_f="13526" txt_i="7272" txt_f="7286">90 (68.3–98.8)</offsets><sup><offsets xml_i="13531" xml_f="13532" txt_i="7286" txt_f="7287">*</offsets></sup></td><td align="center"><offsets xml_i="13562" xml_f="13576" txt_i="7288" txt_f="7302">45 (23.0–68.5)</offsets></td><td align="center"><offsets xml_i="13600" xml_f="13612" txt_i="7303" txt_f="7315">10(1.2–31.7)</offsets></td></tr><tr><td align="left"><offsets xml_i="13643" xml_f="13655" txt_i="7316" txt_f="7328">Forgetfulnes</offsets></td><td align="center"><offsets xml_i="13679" xml_f="13692" txt_i="7329" txt_f="7342">85(62.1–96.8)</offsets><sup><offsets xml_i="13697" xml_f="13698" txt_i="7342" txt_f="7343">*</offsets></sup></td><td align="center"><offsets xml_i="13728" xml_f="13742" txt_i="7344" txt_f="7358">50 (27.2–72.8)</offsets></td><td align="center"><offsets xml_i="13766" xml_f="13779" txt_i="7359" txt_f="7372">15 (3.2–37.9)</offsets></td></tr><tr><td align="left"><offsets xml_i="13810" xml_f="13822" txt_i="7373" txt_f="7385">Paresthesias</offsets></td><td align="center"><offsets xml_i="13846" xml_f="13859" txt_i="7386" txt_f="7399">85(62.1–96.8)</offsets><sup><offsets xml_i="13864" xml_f="13865" txt_i="7399" txt_f="7400">*</offsets></sup></td><td align="center"><offsets xml_i="13895" xml_f="13908" txt_i="7401" txt_f="7414">35(15.4–59.2)</offsets></td><td align="center"><offsets xml_i="13932" xml_f="13945" txt_i="7415" txt_f="7428">30(11.9–54.3)</offsets></td></tr><tr><td align="left"><offsets xml_i="13976" xml_f="13991" txt_i="7429" txt_f="7444">Irritable bowel</offsets></td><td align="center"><offsets xml_i="14015" xml_f="14029" txt_i="7445" txt_f="7459">65 (40.8–84.6)</offsets><sup><offsets xml_i="14034" xml_f="14035" txt_i="7459" txt_f="7460">*</offsets></sup></td><td align="center"><offsets xml_i="14065" xml_f="14077" txt_i="7461" txt_f="7473">10(1.2–31.7)</offsets></td><td align="center"><offsets xml_i="14101" xml_f="14114" txt_i="7474" txt_f="7487">20 (5.7–43.7)</offsets></td></tr><tr><td align="left"><offsets xml_i="14145" xml_f="14159" txt_i="7488" txt_f="7502">Sicca syndrome</offsets></td><td align="center"><offsets xml_i="14183" xml_f="14197" txt_i="7503" txt_f="7517">53 (28.9–75.5)</offsets><sup><offsets xml_i="14202" xml_f="14204" txt_i="7517" txt_f="7519">**</offsets></sup></td><td align="center"><offsets xml_i="14234" xml_f="14248" txt_i="7520" txt_f="7534">45 (23.0–68.5)</offsets></td><td align="center"><offsets xml_i="14272" xml_f="14284" txt_i="7535" txt_f="7547">10(1.2–31.7)</offsets></td></tr><tr><td align="left"><offsets xml_i="14315" xml_f="14326" txt_i="7548" txt_f="7559">Sore throat</offsets></td><td align="center"><offsets xml_i="14350" xml_f="14364" txt_i="7560" txt_f="7574">45 (23.0–68.5)</offsets><sup><offsets xml_i="14369" xml_f="14371" txt_i="7574" txt_f="7576">**</offsets></sup></td><td align="center"><offsets xml_i="14401" xml_f="14413" txt_i="7577" txt_f="7589">25(8.7–49.1)</offsets></td><td align="center"><offsets xml_i="14437" xml_f="14448" txt_i="7590" txt_f="7601">5(0.1–24.9)</offsets></td></tr><tr><td align="left"><offsets xml_i="14479" xml_f="14490" txt_i="7602" txt_f="7613">Acute onset</offsets></td><td align="center"><offsets xml_i="14514" xml_f="14527" txt_i="7614" txt_f="7627">40(19.1–63.9)</offsets><sup><offsets xml_i="14532" xml_f="14533" txt_i="7627" txt_f="7628">*</offsets></sup></td><td align="center"><offsets xml_i="14563" xml_f="14575" txt_i="7629" txt_f="7641">5 (0.1–24.9)</offsets></td><td align="center"><offsets xml_i="14599" xml_f="14608" txt_i="7642" txt_f="7651">0(0–16.8)</offsets></td></tr><tr><td align="left"><offsets xml_i="14639" xml_f="14649" txt_i="7652" txt_f="7662">Cold hands</offsets></td><td align="center"><offsets xml_i="14673" xml_f="14686" txt_i="7663" txt_f="7676">40(19.1–63.9)</offsets><sup><offsets xml_i="14691" xml_f="14693" txt_i="7676" txt_f="7678">**</offsets></sup></td><td align="center"><offsets xml_i="14723" xml_f="14735" txt_i="7679" txt_f="7691">15(3.2–37.9)</offsets></td><td align="center"><offsets xml_i="14759" xml_f="14768" txt_i="7692" txt_f="7701">0(0–16.8)</offsets></td></tr><tr><td align="left"><offsets xml_i="14799" xml_f="14814" txt_i="7702" txt_f="7717">Low grade fever</offsets></td><td align="center"><offsets xml_i="14838" xml_f="14851" txt_i="7718" txt_f="7731">20 (5.7–43.7)</offsets><sup><offsets xml_i="14856" xml_f="14858" txt_i="7731" txt_f="7733">**</offsets></sup></td><td align="center"><offsets xml_i="14888" xml_f="14897" txt_i="7734" txt_f="7743">0(0–16.8)</offsets></td><td align="center"><offsets xml_i="14921" xml_f="14930" txt_i="7744" txt_f="7753">0(0–16.8)</offsets></td></tr><tr><td align="left"><offsets xml_i="14961" xml_f="14984" txt_i="7754" txt_f="7777">Lymph gland enlargement</offsets></td><td align="center"><offsets xml_i="15008" xml_f="15020" txt_i="7778" txt_f="7790">5 (0.1–24.9)</offsets></td><td align="center"><offsets xml_i="15044" xml_f="15056" txt_i="7791" txt_f="7803">5 (0.1–24.9)</offsets></td><td align="center"><offsets xml_i="15080" xml_f="15089" txt_i="7804" txt_f="7813">0(0–16.8)</offsets></td></tr><tr><td align="left"><offsets xml_i="15120" xml_f="15151" txt_i="7814" txt_f="7845">VAS = 10 cm visual analog scale</offsets></td><td></td><td></td><td></td></tr><tr><td align="left"><sup><offsets xml_i="15214" xml_f="15215" txt_i="7849" txt_f="7850">*</offsets></sup><offsets xml_i="15221" xml_f="15256" txt_i="7850" txt_f="7882">=p &lt; 0.05 vs both control groups</offsets></td><td></td><td></td><td></td></tr><tr><td align="left"><sup><offsets xml_i="15319" xml_f="15321" txt_i="7886" txt_f="7888">**</offsets></sup><offsets xml_i="15327" xml_f="15366" txt_i="7888" txt_f="7924"> = p &lt; 0.05 vs healthy controls only</offsets></td><td></td><td></td><td></td></tr></tbody></table></table-wrap><p><offsets xml_i="15435" xml_f="15635" txt_i="7928" txt_f="8128">When compared to RA patients, FM subjects had similar VAS scores in pain perception and morning stiffness. Nevertheless they had higher scores in fatigue, sleep disturbances and disability perception.</offsets></p></sec><sec><title><offsets xml_i="15657" xml_f="15680" txt_i="8130" txt_f="8153">Outcomes and estimation</offsets></title><p><offsets xml_i="15691" xml_f="15867" txt_i="8154" txt_f="8327">Eighty percent of FM patients had NE-evoked pain according to our definition, in contrast 30% of RA patients and 30% of normal controls had such response (p &lt; 0.05) (figure </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="15897" xml_f="15898" txt_i="8327" txt_f="8328">1</offsets></xref><offsets xml_i="15905" xml_f="16093" txt_i="8328" txt_f="8513">). Likewise NE-evoked pain intensity was greater in FM group (mean +/- SD 2.5 +/- 2.5) when compared to RA patients (0.3 +/- 0-7) and healthy controls (0.3 +/- 0.8) p &lt; 0.0001. (Figure </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="16123" xml_f="16124" txt_i="8513" txt_f="8514">2</offsets></xref><offsets xml_i="16131" xml_f="16133" txt_i="8514" txt_f="8516">).</offsets></p><fig position="float" id="F1"><label><offsets xml_i="16174" xml_f="16182" txt_i="8517" txt_f="8525">Figure 1</offsets></label><caption><p><offsets xml_i="16202" xml_f="16228" txt_i="8525" txt_f="8551">Norepinephrine-evoked pain</offsets></p></caption><graphic xlink:href="1471-2474-3-2-1"></graphic></fig><fig position="float" id="F2"><label><offsets xml_i="16333" xml_f="16341" txt_i="8552" txt_f="8560">Figure 2</offsets></label><caption><p><offsets xml_i="16361" xml_f="16387" txt_i="8560" txt_f="8586">Norepinephrine-evoked pain</offsets></p></caption><graphic xlink:href="1471-2474-3-2-2"></graphic></fig><p><offsets xml_i="16458" xml_f="16583" txt_i="8587" txt_f="8712">Response to placebo in FM group (mean +/- SD 0.5 +/- 1.3) was not different when compared to RA group (0.1 +/- 0.2) p = 0.07.</offsets></p></sec><sec><title><offsets xml_i="16605" xml_f="16619" txt_i="8714" txt_f="8728">Adverse events</offsets></title><p><offsets xml_i="16630" xml_f="16700" txt_i="8729" txt_f="8799">Pain induction was severe in two FM patients injected with NE (figure </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="16730" xml_f="16731" txt_i="8799" txt_f="8800">2</offsets></xref><offsets xml_i="16738" xml_f="16784" txt_i="8800" txt_f="8846">). Other adverse events are outlined in table </offsets><xref ref-type="table" rid="T2"><offsets xml_i="16816" xml_f="16817" txt_i="8846" txt_f="8847">2</offsets></xref><offsets xml_i="16824" xml_f="16946" txt_i="8847" txt_f="8969">. Notable was a peculiar spreading of pain to other areas of the extremity seen in 8/20 of FM patients after NE injection.</offsets></p><table-wrap position="float" id="T2"><label><offsets xml_i="16994" xml_f="17001" txt_i="8970" txt_f="8977">Table 2</offsets></label><caption><p><offsets xml_i="17021" xml_f="17105" txt_i="8977" txt_f="9061">Number of cases with adverse events after norepinephrine (NE) and placebo injections</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center" colspan="2"><bold><offsets xml_i="17213" xml_f="17225" txt_i="9063" txt_f="9075">Fibromyalgia</offsets></bold></td><td align="center" colspan="2"><bold><offsets xml_i="17274" xml_f="17294" txt_i="9076" txt_f="9096">Rheumatoid Arthritis</offsets></bold></td><td align="center" colspan="2"><bold><offsets xml_i="17343" xml_f="17359" txt_i="9097" txt_f="9113">Healthy Controls</offsets></bold></td></tr><tr><td></td><td colspan="2"><hr></hr></td><td colspan="2"><hr></hr></td><td colspan="2"><hr></hr></td></tr><tr><td></td><td align="left" colspan="2"><bold><offsets xml_i="17532" xml_f="17540" txt_i="9119" txt_f="9127">(n = 20)</offsets></bold></td><td align="left" colspan="2"><bold><offsets xml_i="17587" xml_f="17595" txt_i="9128" txt_f="9136">(n = 20)</offsets></bold></td><td align="left" colspan="2"><bold><offsets xml_i="17642" xml_f="17650" txt_i="9137" txt_f="9145">(n = 20)</offsets></bold></td></tr></thead><tbody><tr><td></td><td align="center"><offsets xml_i="17714" xml_f="17721" txt_i="9147" txt_f="9154">placebo</offsets></td><td align="center"><offsets xml_i="17745" xml_f="17747" txt_i="9155" txt_f="9157">NE</offsets></td><td align="center"><offsets xml_i="17771" xml_f="17778" txt_i="9158" txt_f="9165">placebo</offsets></td><td align="center"><offsets xml_i="17802" xml_f="17804" txt_i="9166" txt_f="9168">NE</offsets></td><td align="center"><offsets xml_i="17828" xml_f="17835" txt_i="9169" txt_f="9176">placebo</offsets></td><td align="center"><offsets xml_i="17859" xml_f="17861" txt_i="9177" txt_f="9179">NE</offsets></td></tr><tr><td colspan="7"><hr></hr></td></tr><tr><td align="left"><bold><offsets xml_i="17937" xml_f="17954" txt_i="9181" txt_f="9198">Spreading of pain</offsets></bold></td><td align="center"><offsets xml_i="17985" xml_f="17986" txt_i="9199" txt_f="9200">0</offsets></td><td align="center"><offsets xml_i="18010" xml_f="18011" txt_i="9201" txt_f="9202">8</offsets></td><td align="center"><offsets xml_i="18035" xml_f="18036" txt_i="9203" txt_f="9204">0</offsets></td><td align="center"><offsets xml_i="18060" xml_f="18061" txt_i="9205" txt_f="9206">0</offsets></td><td align="center"><offsets xml_i="18085" xml_f="18086" txt_i="9207" txt_f="9208">0</offsets></td><td align="center"><offsets xml_i="18110" xml_f="18111" txt_i="9209" txt_f="9210">0</offsets></td></tr><tr><td align="left"><bold><offsets xml_i="18148" xml_f="18157" txt_i="9211" txt_f="9220">Pale halo</offsets></bold></td><td align="center"><offsets xml_i="18188" xml_f="18189" txt_i="9221" txt_f="9222">0</offsets></td><td align="center"><offsets xml_i="18213" xml_f="18214" txt_i="9223" txt_f="9224">3</offsets></td><td align="center"><offsets xml_i="18238" xml_f="18239" txt_i="9225" txt_f="9226">0</offsets></td><td align="center"><offsets xml_i="18263" xml_f="18264" txt_i="9227" txt_f="9228">1</offsets></td><td align="center"><offsets xml_i="18288" xml_f="18289" txt_i="9229" txt_f="9230">0</offsets></td><td align="center"><offsets xml_i="18313" xml_f="18314" txt_i="9231" txt_f="9232">1</offsets></td></tr><tr><td align="left"><bold><offsets xml_i="18351" xml_f="18363" txt_i="9233" txt_f="9245">Paresthesias</offsets></bold></td><td align="center"><offsets xml_i="18394" xml_f="18395" txt_i="9246" txt_f="9247">5</offsets></td><td align="center"><offsets xml_i="18419" xml_f="18420" txt_i="9248" txt_f="9249">2</offsets></td><td align="center"><offsets xml_i="18444" xml_f="18445" txt_i="9250" txt_f="9251">4</offsets></td><td align="center"><offsets xml_i="18469" xml_f="18470" txt_i="9252" txt_f="9253">3</offsets></td><td align="center"><offsets xml_i="18494" xml_f="18495" txt_i="9254" txt_f="9255">5</offsets></td><td align="center"><offsets xml_i="18519" xml_f="18520" txt_i="9256" txt_f="9257">2</offsets></td></tr><tr><td align="left"><bold><offsets xml_i="18557" xml_f="18569" txt_i="9258" txt_f="9270">Palpitations</offsets></bold></td><td align="center"><offsets xml_i="18600" xml_f="18601" txt_i="9271" txt_f="9272">0</offsets></td><td align="center"><offsets xml_i="18625" xml_f="18626" txt_i="9273" txt_f="9274">1</offsets></td><td align="center"><offsets xml_i="18650" xml_f="18651" txt_i="9275" txt_f="9276">0</offsets></td><td align="center"><offsets xml_i="18675" xml_f="18676" txt_i="9277" txt_f="9278">0</offsets></td><td align="center"><offsets xml_i="18700" xml_f="18701" txt_i="9279" txt_f="9280">0</offsets></td><td align="center"><offsets xml_i="18725" xml_f="18726" txt_i="9281" txt_f="9282">0</offsets></td></tr><tr><td align="left"><bold><offsets xml_i="18763" xml_f="18771" txt_i="9283" txt_f="9291">Sweating</offsets></bold></td><td align="center"><offsets xml_i="18802" xml_f="18803" txt_i="9292" txt_f="9293">0</offsets></td><td align="center"><offsets xml_i="18827" xml_f="18828" txt_i="9294" txt_f="9295">1</offsets></td><td align="center"><offsets xml_i="18852" xml_f="18853" txt_i="9296" txt_f="9297">0</offsets></td><td align="center"><offsets xml_i="18877" xml_f="18878" txt_i="9298" txt_f="9299">0</offsets></td><td align="center"><offsets xml_i="18902" xml_f="18903" txt_i="9300" txt_f="9301">0</offsets></td><td align="center"><offsets xml_i="18927" xml_f="18928" txt_i="9302" txt_f="9303">0</offsets></td></tr><tr><td align="left"><bold><offsets xml_i="18965" xml_f="18980" txt_i="9304" txt_f="9319">Distal swelling</offsets></bold></td><td align="center"><offsets xml_i="19011" xml_f="19012" txt_i="9320" txt_f="9321">0</offsets></td><td align="center"><offsets xml_i="19036" xml_f="19037" txt_i="9322" txt_f="9323">1</offsets></td><td align="center"><offsets xml_i="19061" xml_f="19062" txt_i="9324" txt_f="9325">0</offsets></td><td align="center"><offsets xml_i="19086" xml_f="19087" txt_i="9326" txt_f="9327">0</offsets></td><td align="center"><offsets xml_i="19111" xml_f="19112" txt_i="9328" txt_f="9329">0</offsets></td><td align="center"><offsets xml_i="19136" xml_f="19137" txt_i="9330" txt_f="9331">0</offsets></td></tr></tbody></table></table-wrap></sec><sec><title><offsets xml_i="19194" xml_f="19218" txt_i="9333" txt_f="9357">Discontinued medications</offsets></title><p><offsets xml_i="19229" xml_f="19235" txt_i="9358" txt_f="9364">Table </offsets><xref ref-type="table" rid="T3"><offsets xml_i="19267" xml_f="19268" txt_i="9364" txt_f="9365">3</offsets></xref><offsets xml_i="19275" xml_f="19504" txt_i="9365" txt_f="9594"> shows prescribed non-steroidal analgesic/anti-inflammatory drugs and centrally acting medications with their corresponding plasma half-life. Analgesic/anti-inflammatory drugs were discontinued at least 24 hours before the study.</offsets></p><table-wrap position="float" id="T3"><label><offsets xml_i="19552" xml_f="19559" txt_i="9595" txt_f="9602">Table 3</offsets></label><caption><p><offsets xml_i="19579" xml_f="19784" txt_i="9602" txt_f="9807">Prescribed non-steroidal anti-inflammatory drugs and centrally acting agents. (*) means that the drug was discontinued at least 24 hrs before the study. Plasma half-life of each compound is also indicated.</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center" colspan="3"><bold><offsets xml_i="19883" xml_f="19895" txt_i="9808" txt_f="9820">Fibromyalgia</offsets></bold></td><td align="center" colspan="3"><bold><offsets xml_i="19944" xml_f="19964" txt_i="9821" txt_f="9841">Rheumatoid Arthritis</offsets></bold></td></tr></thead><tbody><tr><td align="center"><bold><offsets xml_i="20025" xml_f="20029" txt_i="9842" txt_f="9846">Drug</offsets></bold></td><td align="center"><bold><offsets xml_i="20066" xml_f="20084" txt_i="9847" txt_f="9865">Number of patients</offsets></bold></td><td align="center"><bold><offsets xml_i="20121" xml_f="20145" txt_i="9866" txt_f="9890">Plasma half-life (hours)</offsets></bold></td><td align="center"><offsets xml_i="20176" xml_f="20180" txt_i="9891" txt_f="9895">Drug</offsets></td><td align="center"><bold><offsets xml_i="20210" xml_f="20228" txt_i="9896" txt_f="9914">Number of patients</offsets></bold></td><td align="center"><bold><offsets xml_i="20265" xml_f="20289" txt_i="9915" txt_f="9939">Plasma half-life (hours)</offsets></bold></td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left"><offsets xml_i="20366" xml_f="20376" txt_i="9941" txt_f="9951">clonazepam</offsets></td><td align="center"><offsets xml_i="20400" xml_f="20401" txt_i="9952" txt_f="9953">6</offsets></td><td align="center"><offsets xml_i="20425" xml_f="20430" txt_i="9954" txt_f="9959">20–60</offsets></td><td align="left"><offsets xml_i="20452" xml_f="20465" txt_i="9960" txt_f="9973">acetaminophen</offsets><sup><offsets xml_i="20470" xml_f="20471" txt_i="9973" txt_f="9974">*</offsets></sup></td><td align="center"><offsets xml_i="20501" xml_f="20502" txt_i="9975" txt_f="9976">4</offsets></td><td align="center"><offsets xml_i="20526" xml_f="20529" txt_i="9977" txt_f="9980">4–6</offsets></td></tr><tr><td align="left"><offsets xml_i="20560" xml_f="20573" txt_i="9981" txt_f="9994">acetaminophen</offsets><sup><offsets xml_i="20578" xml_f="20579" txt_i="9994" txt_f="9995">*</offsets></sup></td><td align="center"><offsets xml_i="20609" xml_f="20610" txt_i="9996" txt_f="9997">5</offsets></td><td align="center"><offsets xml_i="20634" xml_f="20637" txt_i="9998" txt_f="10001">4–6</offsets></td><td align="left"><offsets xml_i="20659" xml_f="20668" txt_i="10002" txt_f="10011">celecoxib</offsets><sup><offsets xml_i="20673" xml_f="20674" txt_i="10011" txt_f="10012">*</offsets></sup></td><td align="center"><offsets xml_i="20704" xml_f="20705" txt_i="10013" txt_f="10014">3</offsets></td><td align="center"><offsets xml_i="20729" xml_f="20734" txt_i="10015" txt_f="10020">10–12</offsets></td></tr><tr><td align="left"><offsets xml_i="20765" xml_f="20774" txt_i="10021" txt_f="10030">mianserin</offsets></td><td align="center"><offsets xml_i="20798" xml_f="20799" txt_i="10031" txt_f="10032">2</offsets></td><td align="center"><offsets xml_i="20823" xml_f="20828" txt_i="10033" txt_f="10038">21–61</offsets></td><td align="left"><offsets xml_i="20850" xml_f="20860" txt_i="10039" txt_f="10049">diclofenac</offsets><sup><offsets xml_i="20865" xml_f="20866" txt_i="10049" txt_f="10050">*</offsets></sup></td><td align="center"><offsets xml_i="20896" xml_f="20897" txt_i="10051" txt_f="10052">3</offsets></td><td align="center"><offsets xml_i="20921" xml_f="20924" txt_i="10053" txt_f="10056">3–7</offsets></td></tr><tr><td align="left"><offsets xml_i="20955" xml_f="20965" txt_i="10057" txt_f="10067">alprazolam</offsets></td><td align="center"><offsets xml_i="20989" xml_f="20990" txt_i="10068" txt_f="10069">2</offsets></td><td align="center"><offsets xml_i="21014" xml_f="21019" txt_i="10070" txt_f="10075">12–15</offsets></td><td align="left"><offsets xml_i="21041" xml_f="21050" txt_i="10076" txt_f="10085">piroxicam</offsets><sup><offsets xml_i="21055" xml_f="21056" txt_i="10085" txt_f="10086">*</offsets></sup></td><td align="center"><offsets xml_i="21086" xml_f="21087" txt_i="10087" txt_f="10088">2</offsets></td><td align="center"><offsets xml_i="21111" xml_f="21116" txt_i="10089" txt_f="10094">34–50</offsets></td></tr><tr><td align="left"><offsets xml_i="21147" xml_f="21157" txt_i="10095" txt_f="10105">bromazepam</offsets></td><td align="center"><offsets xml_i="21181" xml_f="21182" txt_i="10106" txt_f="10107">1</offsets></td><td align="center"><offsets xml_i="21206" xml_f="21208" txt_i="10108" txt_f="10110">20</offsets></td><td align="left"><offsets xml_i="21230" xml_f="21240" txt_i="10111" txt_f="10121">clonazepam</offsets></td><td align="center"><offsets xml_i="21264" xml_f="21265" txt_i="10122" txt_f="10123">1</offsets></td><td align="center"><offsets xml_i="21289" xml_f="21294" txt_i="10124" txt_f="10129">20–60</offsets></td></tr><tr><td align="left"><offsets xml_i="21325" xml_f="21334" txt_i="10130" txt_f="10139">triazolam</offsets></td><td align="center"><offsets xml_i="21358" xml_f="21359" txt_i="10140" txt_f="10141">1</offsets></td><td align="center"><offsets xml_i="21383" xml_f="21390" txt_i="10142" txt_f="10149">1.5–5.5</offsets></td><td align="left"><offsets xml_i="21412" xml_f="21422" txt_i="10150" txt_f="10160">alprazolam</offsets></td><td align="center"><offsets xml_i="21446" xml_f="21447" txt_i="10161" txt_f="10162">1</offsets></td><td align="center"><offsets xml_i="21471" xml_f="21476" txt_i="10163" txt_f="10168">12–15</offsets></td></tr><tr><td align="left"><offsets xml_i="21507" xml_f="21516" txt_i="10169" txt_f="10178">piroxicam</offsets><sup><offsets xml_i="21521" xml_f="21522" txt_i="10178" txt_f="10179">*</offsets></sup></td><td align="center"><offsets xml_i="21552" xml_f="21553" txt_i="10180" txt_f="10181">1</offsets></td><td align="center"><offsets xml_i="21577" xml_f="21582" txt_i="10182" txt_f="10187">34–50</offsets></td><td align="left"><offsets xml_i="21604" xml_f="21616" txt_i="10188" txt_f="10200">indomethacin</offsets><sup><offsets xml_i="21621" xml_f="21622" txt_i="10200" txt_f="10201">*</offsets></sup></td><td align="center"><offsets xml_i="21652" xml_f="21653" txt_i="10202" txt_f="10203">1</offsets></td><td align="center"><offsets xml_i="21677" xml_f="21680" txt_i="10204" txt_f="10207">4–5</offsets></td></tr><tr><td align="left"><offsets xml_i="21711" xml_f="21720" txt_i="10208" txt_f="10217">celecoxib</offsets><sup><offsets xml_i="21725" xml_f="21726" txt_i="10217" txt_f="10218">*</offsets></sup></td><td align="center"><offsets xml_i="21756" xml_f="21757" txt_i="10219" txt_f="10220">1</offsets></td><td align="center"><offsets xml_i="21781" xml_f="21786" txt_i="10221" txt_f="10226">10–12</offsets></td><td align="left"><offsets xml_i="21808" xml_f="21815" txt_i="10227" txt_f="10234">aspirin</offsets><sup><offsets xml_i="21820" xml_f="21821" txt_i="10234" txt_f="10235">*</offsets></sup></td><td align="center"><offsets xml_i="21851" xml_f="21852" txt_i="10236" txt_f="10237">1</offsets></td><td align="center"><offsets xml_i="21876" xml_f="21879" txt_i="10238" txt_f="10241">2–3</offsets></td></tr><tr><td align="left"><offsets xml_i="21910" xml_f="21920" txt_i="10242" txt_f="10252">ketoprofen</offsets><sup><offsets xml_i="21925" xml_f="21926" txt_i="10252" txt_f="10253">*</offsets></sup></td><td align="center"><offsets xml_i="21956" xml_f="21957" txt_i="10254" txt_f="10255">1</offsets></td><td align="center"><offsets xml_i="21981" xml_f="21986" txt_i="10256" txt_f="10261">1.5–4</offsets></td><td align="left"><offsets xml_i="22008" xml_f="22017" txt_i="10262" txt_f="10271">rofecoxib</offsets><sup><offsets xml_i="22022" xml_f="22023" txt_i="10271" txt_f="10272">*</offsets></sup></td><td align="center"><offsets xml_i="22053" xml_f="22054" txt_i="10273" txt_f="10274">1</offsets></td><td align="center"><offsets xml_i="22078" xml_f="22080" txt_i="10275" txt_f="10277">17</offsets></td></tr><tr><td align="left"><offsets xml_i="22111" xml_f="22121" txt_i="10278" txt_f="10288">fluoxetine</offsets></td><td align="center"><offsets xml_i="22145" xml_f="22146" txt_i="10289" txt_f="10290">1</offsets></td><td align="center"><offsets xml_i="22170" xml_f="22176" txt_i="10291" txt_f="10297">96–144</offsets></td><td align="left"><offsets xml_i="22198" xml_f="22207" txt_i="10298" txt_f="10307">ibuprofen</offsets><sup><offsets xml_i="22212" xml_f="22213" txt_i="10307" txt_f="10308">*</offsets></sup></td><td align="center"><offsets xml_i="22243" xml_f="22244" txt_i="10309" txt_f="10310">1</offsets></td><td align="center"><offsets xml_i="22268" xml_f="22271" txt_i="10311" txt_f="10314">2–3</offsets></td></tr><tr><td align="left"><offsets xml_i="22302" xml_f="22312" txt_i="10315" txt_f="10325">gabapentin</offsets><sup><offsets xml_i="22317" xml_f="22318" txt_i="10325" txt_f="10326">*</offsets></sup></td><td align="center"><offsets xml_i="22348" xml_f="22349" txt_i="10327" txt_f="10328">1</offsets></td><td align="center"><offsets xml_i="22373" xml_f="22376" txt_i="10329" txt_f="10332">5–9</offsets></td><td align="left"><offsets xml_i="22398" xml_f="22408" txt_i="10333" txt_f="10343">gabapentin</offsets><sup><offsets xml_i="22413" xml_f="22414" txt_i="10343" txt_f="10344">*</offsets></sup></td><td align="center"><offsets xml_i="22444" xml_f="22445" txt_i="10345" txt_f="10346">1</offsets></td><td align="center"><offsets xml_i="22469" xml_f="22472" txt_i="10347" txt_f="10350">5–9</offsets></td></tr></tbody></table></table-wrap></sec></sec><sec><title><offsets xml_i="22535" xml_f="22545" txt_i="10353" txt_f="10363">Discussion</offsets></title><sec><title><offsets xml_i="22565" xml_f="22579" txt_i="10364" txt_f="10378">Interpretation</offsets></title><p><offsets xml_i="22590" xml_f="23075" txt_i="10379" txt_f="10864">Our double blind study demonstrates that most FM patients have NE-evoked pain. This type of response was significantly different from the response observed in another chronic painful condition, rheumatoid arthritis, and also different from healthy controls. Furthermore, the intensity of NE-evoked pain was greater in FM subjects when compared to the other two control groups. These results give experimental support to the notion that FM is a sympathetically maintained pain syndrome.</offsets></p></sec><sec><title><offsets xml_i="23097" xml_f="23113" txt_i="10866" txt_f="10882">Generalizability</offsets></title><p><offsets xml_i="23124" xml_f="23542" txt_i="10883" txt_f="11301">We recognize limitations in our study; although we used a double blind protocol, nevertheless patient's diagnosis (FM, RA or healthy control) could not be blinded to the physician who performed the injections. We believe this fact did not bias the results since all participants were given the same information on what to expect from the injections. Such information was basically what was written in the consent form.</offsets></p><p><offsets xml_i="23549" xml_f="24023" txt_i="11302" txt_f="11776">Our study did not explore the specificity of the hyperalgesic response to NE in the FM group. To test this possibility it would be necessary to first perform sympathetic blockade and latter attempt to rekindle pain with NE. Another possible approach would be an additional intervention injecting NE mixed with an adrenergic blocking agent. Nevertheless, such approach has theoretical shortcomings as some adrenergic blocking agents also have intrinsic anesthetic properties.</offsets></p><p><offsets xml_i="24030" xml_f="24438" txt_i="11777" txt_f="12185">The 24 hours period of analgesic/anti-inflammatory drugs discontinuation may have been insufficient for the patients to be free of long acting medications effects. Likewise centrally acting drugs may have blunted the response to NE. Nevertheless we believe these circumstances did not impact the results as only 3 patients (2 with RA and 1 with FM) were taking long-acting compounds such as piroxicam (table </offsets><xref ref-type="table" rid="T3"><offsets xml_i="24470" xml_f="24471" txt_i="12185" txt_f="12186">3</offsets></xref><offsets xml_i="24478" xml_f="24640" txt_i="12186" txt_f="12348">). Of the ten FM patients that were on centrally acting drugs 7 had NE-evoked pain, similarly 9/10 FM subjects that were not taking such drugs had NE-evoked pain.</offsets></p><p><offsets xml_i="24647" xml_f="25289" txt_i="12349" txt_f="12991">The injected dosages of 10 micrograms of NE were based on what was previously reported in the neuropathic pain literature and also on a pre-trial NE injections in ourselves that demonstrated no untoward effects and no pain elicitation with this dosage. Future studies may find more appropriate NE dosages as well as different routes of administration such as transdermal patches, and perhaps different dilutions to cover a wider area and thus possibly better discriminate the hyperalgesic response of patients from controls. We speculate about the possibility that once perfected, NE-evoked pain may evolve into a useful clinical test for FM.</offsets></p></sec><sec><title><offsets xml_i="25311" xml_f="25327" txt_i="12993" txt_f="13009">Overall evidence</offsets></title><p><offsets xml_i="25338" xml_f="25477" txt_i="13010" txt_f="13149">The first study of autonomic nervous system function in FM was a controlled therapeutic trial reported by Bengtsson and Bentgsson in 1988 [</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="25509" xml_f="25511" txt_i="13149" txt_f="13151">15</offsets></xref><offsets xml_i="25518" xml_f="25877" txt_i="13151" txt_f="13510">]. They described that anesthetic blockade of the sympathetic stellate ganglion, markedly decreased regional pain and tender points in contrast to the lack of effect of sham placebo injection into the neck area. Subsequently Vaeroy et al. using Doppler probes showed that FM patients have diminished distal vasomotor response to acoustic or cold stimulation [</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="25909" xml_f="25911" txt_i="13510" txt_f="13512">16</offsets></xref><offsets xml_i="25918" xml_f="26193" txt_i="13512" txt_f="13787">]. With the introduction in recent years of a new powerful technique, heart rate variability analysis, several groups of investigators demonstrated that FM subjects have changes consistent with relentless sympathetic hyperactivity with concurrent hypo-reactivity to stress. [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="26224" xml_f="26225" txt_i="13787" txt_f="13788">1</offsets></xref><offsets xml_i="26232" xml_f="26233" txt_i="13788" txt_f="13789">-</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="26264" xml_f="26265" txt_i="13789" txt_f="13790">6</offsets></xref><offsets xml_i="26272" xml_f="26375" txt_i="13790" txt_f="13893">]. This accumulated evidence led to propose that FM may be a sympathetically maintained pain syndrome [</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="26406" xml_f="26407" txt_i="13893" txt_f="13894">7</offsets></xref><offsets xml_i="26414" xml_f="26416" txt_i="13894" txt_f="13896">].</offsets></p><p><offsets xml_i="26423" xml_f="26707" txt_i="13897" txt_f="14181">Sympathetically maintained pain is characterized by its frequent post-traumatic onset, by the presence of chronic stimuli-independent pain that is accompanied by allodynia, paresthesias and distal vasomotor changes. Typically, this type of pain is diminished by sympathetic blockade [</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="26739" xml_f="26741" txt_i="14181" txt_f="14183">17</offsets></xref><offsets xml_i="26748" xml_f="26908" txt_i="14183" txt_f="14343">]. FM pain has such characteristics. It is well known that FM syndrome has frequent post-traumatic onset particularly when the trauma is directed to neck area [</offsets><xref ref-type="bibr" rid="B18"><offsets xml_i="26940" xml_f="26942" txt_i="14343" txt_f="14345">18</offsets></xref><offsets xml_i="26949" xml_f="27177" txt_i="14345" txt_f="14573">], a site with unique superficial sympathetic ganglia network. Pain in FM is clearly stimuli-independent, as no underlying peripheral tissue damage has been identified. FM tender points reflect a state of generalized allodynia [</offsets><xref ref-type="bibr" rid="B19"><offsets xml_i="27209" xml_f="27211" txt_i="14573" txt_f="14575">19</offsets></xref><offsets xml_i="27218" xml_f="27324" txt_i="14575" txt_f="14681">]. Paresthesias are more frequent in FM when compared to patients with other systemic rheumatic diseases [</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="27356" xml_f="27358" txt_i="14681" txt_f="14683">12</offsets></xref><offsets xml_i="27365" xml_f="27450" txt_i="14683" txt_f="14768">]. In FM there are distal vasomotor changes manifested as pseudo-Raynaud phenomenon [</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="27482" xml_f="27484" txt_i="14768" txt_f="14770">16</offsets></xref><offsets xml_i="27491" xml_f="27608" txt_i="14770" txt_f="14887">] and soft tissue swelling. Finally as mentioned before, FM pain appears to be submissive to sympatholytic maneuvers.</offsets></p><p><offsets xml_i="27615" xml_f="27792" txt_i="14888" txt_f="15065">In addition to the pain syndrome, sympathetic hyperactivity may explain other typical manifestations of FM such as sleep problems, irritable bowel, sicca symptoms, and anxiety [</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="27823" xml_f="27824" txt_i="15065" txt_f="15066">8</offsets></xref><offsets xml_i="27831" xml_f="27999" txt_i="15066" txt_f="15234">]. The concurrent sympathetic hyporeactivity that these patients display (probably due to a ceiling effect) provides a coherent explanation for their constant fatigue [</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="28030" xml_f="28031" txt_i="15234" txt_f="15235">8</offsets></xref><offsets xml_i="28038" xml_f="28039" txt_i="15235" txt_f="15236">]</offsets></p></sec></sec><sec><title><offsets xml_i="28067" xml_f="28077" txt_i="15239" txt_f="15249">Conclusion</offsets></title><p><offsets xml_i="28088" xml_f="28216" txt_i="15250" txt_f="15378">FM patients have NE-evoked pain. This finding supports the hypothesis that FM may be a sympathetically maintained pain syndrome.</offsets></p></sec><sec><title><offsets xml_i="28238" xml_f="28257" txt_i="15380" txt_f="15399">Competing interests</offsets></title><p><offsets xml_i="28268" xml_f="28281" txt_i="15400" txt_f="15413">None declared</offsets></p></sec><sec><title><offsets xml_i="28303" xml_f="28326" txt_i="15415" txt_f="15438">Pre-publication history</offsets></title><p><offsets xml_i="28337" xml_f="28401" txt_i="15439" txt_f="15503">The pre-publication history for this paper can be accessed here:</offsets></p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2474/3/2/prepub"></ext-link></p></sec></body><back><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martinez-Lavin</surname><given-names>M</given-names></name><name><surname>Hermosillo</surname><given-names>AG</given-names></name><name><surname>Mendoza</surname><given-names>C</given-names></name><name><surname>Ortiz</surname><given-names>R</given-names></name><name><surname>Cajigas</surname><given-names>JC</given-names></name><name><surname>Pineda</surname><given-names>C</given-names></name><name><surname>Nava</surname><given-names>A</given-names></name><name><surname>Vallejo</surname><given-names>M</given-names></name></person-group><article-title>Orthostatic sympathetic derangement in subject with fibromyalgia.</article-title><source>J Rheumatol</source><year>1997</year><volume>24</volume><fpage>714</fpage><lpage>718</lpage><pub-id pub-id-type="pmid">9101507</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martinez-Lavin</surname><given-names>M</given-names></name><name><surname>Hermosillo</surname><given-names>AG</given-names></name><name><surname>Rosas</surname><given-names>M</given-names></name><name><surname>Soto</surname><given-names>ME</given-names></name></person-group><article-title>Circadian studies of autonomic nervous balance in patients with fibromyalgia. A heart rate variability analysis.</article-title><source>Arthritis Rheum</source><year>1998</year><volume>41</volume><fpage>1966</fpage><lpage>1971</lpage><pub-id pub-id-type="pmid">9811051</pub-id><pub-id pub-id-type="doi">10.1002/1529-0131(199811)41:11&lt;1966::AID-ART11&gt;3.0.CO;2-O</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kelemen</surname><given-names>J</given-names></name><name><surname>Lang</surname><given-names>E</given-names></name><name><surname>Balint</surname><given-names>G</given-names></name><name><surname>Trocsanyi</surname><given-names>M</given-names></name><name><surname>Muller</surname><given-names>W</given-names></name></person-group><article-title>Orthostatic sympathetic derangement of baroreflex in patients with fibromyalgia.</article-title><source>J Rheumatol</source><year>1998</year><volume>25</volume><fpage>823</fpage><lpage>825</lpage><pub-id pub-id-type="pmid">9558200</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Raj</surname><given-names>RR</given-names></name><name><surname>Brouillard</surname><given-names>D</given-names></name><name><surname>Simpsom</surname><given-names>CS</given-names></name><name><surname>Hopman</surname><given-names>WM</given-names></name><name><surname>Abdollah</surname><given-names>H</given-names></name></person-group><article-title>Dysautonomia among patients with fibromyalgia: A noninvasive assessment.</article-title><source>J Rheumatol</source><year>2000</year><volume>27</volume><fpage>2660</fpage><lpage>2665</lpage><pub-id pub-id-type="pmid">11093450</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>H</given-names></name><name><surname>Neumann</surname><given-names>L</given-names></name><name><surname>Shore</surname><given-names>M</given-names></name><name><surname>Amir</surname><given-names>M</given-names></name><name><surname>Cassuto</surname><given-names>Y</given-names></name><name><surname>Buskila</surname><given-names>D</given-names></name></person-group><article-title>Autonomic dysfunction in patients with fibromyalgia: application of power spectral analysis of heart rate variability.</article-title><source>Semin Arthritis Rheum</source><year>2000</year><volume>29</volume><fpage>217</fpage><lpage>227</lpage><pub-id pub-id-type="pmid">10707990</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>H</given-names></name><name><surname>Neumann</surname><given-names>L</given-names></name><name><surname>Alhosshle</surname><given-names>A</given-names></name><name><surname>Kotler</surname><given-names>M</given-names></name><name><surname>Abu-Shakra</surname><given-names>M</given-names></name><name><surname>Buskila</surname><given-names>D</given-names></name></person-group><article-title>Abnormal sympathovagal balance in men with fibromyalgia.</article-title><source>J Rheumatol</source><year>2001</year><volume>28</volume><fpage>581</fpage><lpage>589</lpage><pub-id pub-id-type="pmid">11296963</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martinez-Lavin</surname><given-names>M</given-names></name></person-group><article-title>Is fibromyalgia a generalised reflex sympathetic dystrophy?.</article-title><source>clin Exp Rheumatol</source><year>2001</year><volume>19</volume><fpage>1</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">11247309</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martinez-Lavin</surname><given-names>M</given-names></name><name><surname>Hermosillo</surname><given-names>AG</given-names></name></person-group><article-title>Autonomic nervous system dysfunction may explain the multisystem features of fibromyalgia.</article-title><source>Semin Arthritis Rheum</source><year>2000</year><volume>29</volume><fpage>197</fpage><lpage>199</lpage><pub-id pub-id-type="pmid">10707988</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ali</surname><given-names>Z</given-names></name><name><surname>Raja</surname><given-names>SN</given-names></name><name><surname>Wesselmann</surname><given-names>U</given-names></name><name><surname>Fuchs</surname><given-names>PN</given-names></name><name><surname>Meyer</surname><given-names>RA</given-names></name><name><surname>Campbell</surname><given-names>JN</given-names></name></person-group><article-title>Intradermal injection of norepinephrine evokes pain in patients with sympathetically maintained pain.</article-title><source>Pain</source><year>2000</year><volume>88</volume><fpage>161</fpage><lpage>68</lpage><pub-id pub-id-type="pmid">11050371</pub-id><pub-id pub-id-type="doi">10.1016/S0304-3959(00)00327-4</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Torebjork</surname><given-names>E</given-names></name><name><surname>Wahren</surname><given-names>L</given-names></name><name><surname>Wallin</surname><given-names>G</given-names></name><name><surname>Hallin</surname><given-names>R</given-names></name><name><surname>Koltzenburg</surname><given-names>M</given-names></name></person-group><article-title>Noradrenaline-evoked pain in neuralgia.</article-title><source>Pain</source><year>1995</year><volume>63</volume><fpage>11</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">8577481</pub-id><pub-id pub-id-type="doi">10.1016/0304-3959(95)00140-N</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>KD</given-names></name><name><surname>Treede</surname><given-names>RD</given-names></name><name><surname>Raja</surname><given-names>SN</given-names></name><name><surname>Meyer</surname><given-names>RA</given-names></name><name><surname>Campbell</surname><given-names>JN</given-names></name></person-group><article-title>Topical application of clonidine relieves hyperalgesia in patients with sympathetically maintained pain.</article-title><source>Pain</source><year>1991</year><volume>47</volume><fpage>309</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">1664508</pub-id><pub-id pub-id-type="doi">10.1016/0304-3959(91)90221-I</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wolfe</surname><given-names>F</given-names></name><name><surname>Smythe</surname><given-names>HA</given-names></name><name><surname>Yunus</surname><given-names>MB</given-names></name><name><surname>Bennet</surname><given-names>RM</given-names></name><name><surname>Bombardier</surname><given-names>C</given-names></name><name><surname>Goldenberg</surname><given-names>DL</given-names></name><name><surname>Tugwell</surname><given-names>P</given-names></name><name><surname>Campbell</surname><given-names>SM</given-names></name><name><surname>Abeles</surname><given-names>M</given-names></name><name><surname>dark</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: Report of the Multicenter Criteria Committee.</article-title><source>Arthritis Rheum</source><year>1990</year><volume>33</volume><fpage>160</fpage><lpage>171</lpage><pub-id pub-id-type="pmid">2306288</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arnett</surname><given-names>FC</given-names></name><name><surname>Edworthy</surname><given-names>SM</given-names></name><name><surname>Bloch</surname><given-names>DA</given-names></name><name><surname>McShane</surname><given-names>DJ</given-names></name><name><surname>Fries</surname><given-names>JF</given-names></name><name><surname>Cooper</surname><given-names>NS</given-names></name><name><surname>Healy</surname><given-names>LA</given-names></name><name><surname>Kaplan</surname><given-names>SR</given-names></name><name><surname>Liang</surname><given-names>MH</given-names></name><name><surname>Luthra</surname><given-names>HS</given-names></name><etal></etal></person-group><article-title>The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.</article-title><source>Arthritis Rheum</source><year>1988</year><volume>31</volume><fpage>315</fpage><lpage>324</lpage><pub-id pub-id-type="pmid">3358796</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fukuda</surname><given-names>K</given-names></name><name><surname>Strauss</surname><given-names>SE</given-names></name><name><surname>Hickie</surname><given-names>I</given-names></name><name><surname>Sharpe</surname><given-names>MC</given-names></name><name><surname>Dobbins</surname><given-names>JG</given-names></name><name><surname>Komaroff</surname><given-names>A</given-names></name></person-group><article-title>The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group.</article-title><source>Ann Intern Med</source><year>1994</year><volume>121</volume><fpage>953</fpage><lpage>959</lpage><pub-id pub-id-type="pmid">7978722</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bengtsson</surname><given-names>A</given-names></name><name><surname>Bengtsson</surname><given-names>M</given-names></name></person-group><article-title>Regional sympathetic blockade in primary fibromyalgia.</article-title><source>Pain</source><year>1988</year><volume>33</volume><fpage>161</fpage><lpage>167</lpage><pub-id pub-id-type="pmid">3380557</pub-id><pub-id pub-id-type="doi">10.1016/0304-3959(88)90086-3</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vaeroy</surname><given-names>H</given-names></name><name><surname>Qiao</surname><given-names>Z</given-names></name><name><surname>Morkrid</surname><given-names>L</given-names></name><name><surname>Forre</surname><given-names>O</given-names></name></person-group><article-title>Altered sympathetic nervous system response in patients with fibromyalgia.</article-title><source>J Rheumatol</source><year>1989</year><volume>16</volume><fpage>1460</fpage><lpage>1465</lpage><pub-id pub-id-type="pmid">2689647</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blumberg</surname><given-names>H</given-names></name><name><surname>Hoffman</surname><given-names>U</given-names></name><name><surname>Mohadjer</surname><given-names>M</given-names></name><name><surname>Scheremet</surname><given-names>R</given-names></name></person-group><article-title>Sympathetic nervous system and pain: a clinical reappraisal.</article-title><source>Behav Brain Sci</source><year>1997</year><volume>20</volume><fpage>426</fpage><lpage>436</lpage><pub-id pub-id-type="pmid">10097005</pub-id><pub-id pub-id-type="doi">10.1017/S0140525X97271487</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Buskila</surname><given-names>D</given-names></name><name><surname>Neumann</surname><given-names>L</given-names></name><name><surname>Vaisberg</surname><given-names>G</given-names></name><name><surname>Alkalay</surname><given-names>D</given-names></name><name><surname>Wolfe</surname><given-names>F</given-names></name></person-group><article-title>Increased rates of fibromyalgia following cervical spine injury. A controlled study of 161 cases of traumatic injury.</article-title><source>Arthritis Rheum</source><year>1997</year><volume>40</volume><fpage>446</fpage><lpage>452</lpage><pub-id pub-id-type="pmid">9082932</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Russell</surname><given-names>J</given-names></name></person-group><article-title>Advances in fibromyalgia: possible role for central neurochemicals.</article-title><source>Am J Med Sci</source><year>1998</year><volume>315</volume><fpage>377</fpage><lpage>384</lpage><pub-id pub-id-type="pmid">9638894</pub-id><pub-id pub-id-type="doi">10.1097/00000441-199806000-00006</pub-id></citation></ref></ref-list></back></article>